Mural Oncology Statistics
Total Valuation
Mural Oncology has a market cap or net worth of $45.48 million. The enterprise value is -$90.97 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, before market open.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mural Oncology has 17.23 million shares outstanding. The number of shares has increased by 1.59% in one year.
| Current Share Class | 17.23M |
| Shares Outstanding | 17.23M |
| Shares Change (YoY) | +1.59% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 0.41% |
| Owned by Institutions (%) | 29.02% |
| Float | 11.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.34 |
| P/TBV Ratio | 0.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.84, with a Debt / Equity ratio of 0.06.
| Current Ratio | 5.84 |
| Quick Ratio | 5.53 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -63.57% and return on invested capital (ROIC) is -40.44%.
| Return on Equity (ROE) | -63.57% |
| Return on Assets (ROA) | -36.68% |
| Return on Invested Capital (ROIC) | -40.44% |
| Return on Capital Employed (ROCE) | -96.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.11M |
| Employee Count | 116 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.87% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -27.87% |
| 50-Day Moving Average | 2.90 |
| 200-Day Moving Average | 3.34 |
| Relative Strength Index (RSI) | 57.82 |
| Average Volume (20 Days) | 14,102,212 |
Short Selling Information
The latest short interest is 594,487, so 3.45% of the outstanding shares have been sold short.
| Short Interest | 594,487 |
| Short Previous Month | 406,115 |
| Short % of Shares Out | 3.45% |
| Short % of Float | 5.03% |
| Short Ratio (days to cover) | 1.48 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -138.26M |
| Pretax Income | n/a |
| Net Income | -128.51M |
| EBITDA | -134.75M |
| EBIT | -138.26M |
| Earnings Per Share (EPS) | -$7.58 |
Full Income StatementBalance Sheet
The company has $144.39 million in cash and $8.02 million in debt, giving a net cash position of $136.36 million or $7.92 per share.
| Cash & Cash Equivalents | 144.39M |
| Total Debt | 8.02M |
| Net Cash | 136.36M |
| Net Cash Per Share | $7.92 |
| Equity (Book Value) | 140.50M |
| Book Value Per Share | 8.22 |
| Working Capital | 126.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$128.55 million and capital expenditures -$92,000, giving a free cash flow of -$128.64 million.
| Operating Cash Flow | -128.55M |
| Capital Expenditures | -92,000 |
| Free Cash Flow | -128.64M |
| FCF Per Share | -$7.47 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |